CD7 and hematopoietic and lymphoid system neoplasm: Conversely, blood cancers consistently reach ORRs of 70–90% with CD19- or CD7-targeted CAR-T cells [322–324], including an 89% ORR in CD19-positive B-cell malignancies and 87% complete remission in CD7-targeted T-cell malignancies [323, 324].